US2011086052A1PendingUtilityA1

Activation of innate and adaptive immune responses by a ginseng extract

45
Individually held — no corporate assignee on recordPriority: Feb 29, 2008Filed: Feb 27, 2009Published: Apr 14, 2011
Est. expiryFeb 29, 2028(~1.6 yrs left)· nominal 20-yr term from priority
Inventors:Darryl J. AdamkoKenneth L. RosenthalJacqueline ShanYingqi WuSharla Sutherland
A61P 31/16A61P 37/04A61P 37/08A61P 43/00A61P 35/00A61P 31/18A61P 31/12A61P 31/04A61P 31/22A61P 11/06A61K 36/25A61K 36/258
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to ginseng fractions and methods for activating innate and adaptive immune responses to prevent, treat or ameliorate a condition in a subject by administering to the subject an effective amount of a ginseng traction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers, or a food item comprising the fraction. The fraction may be made from Panax quinquefolius ' or may be selected from CVT-E002, PQ 2 , PQ 223 and purified fractions from CVT-E002, PQ 2 and PQ 223 .

Claims

exact text as granted — not AI-modified
1 . A method of preventing, treating or ameliorating a condition susceptible to prevention, treatment or amelioration by activation of innate immunity signaling in a subject in need of such treatment, comprising administering to the subject an effective amount of at least one ginseng fraction. 
     
     
         2 . The method of  claim 1 , wherein the condition is selected from the group consisting of an allergy, asthma, viral infection, microbial infection and cancer. 
     
     
         3 . The method of  claim 2 , wherein the viral infection is from a respiratory or mucosally transmitted virus including influenza, corona virus, herpes, respiratory syncytial virus, Rhabdoviridae, and human immunodeficiency virus. 
     
     
         4 . The method of  claim 2 , wherein the fraction is made from a ginseng selected from the group consisting of  Panax quinquefolius, Panax trifolia, Panax ginseng, Panax japonicus, Panax schinseng, Panax notoginseng, Panax pseudoginseng, Panax vietnamensis, Panax elegatior, Panax wangianus, Panax bipinratifidus , green or fresh ginseng, white ginseng, and red ginseng. 
     
     
         5 . The method of  claim 4 , wherein the fraction is a fraction of  Panax quinquefolius.    
     
     
         6 . The method of  claim 5 , wherein the fraction is selected from the group consisting of CVT-E002, PQ 2 , PQ 223  and purified fractions from CVT-E002, PQ 2  and PQ 223 . 
     
     
         7 . The method of  claim 6 , wherein the fraction is CVT-E002. 
     
     
         8 . The method of  claim 7 , wherein CVT-E002 modulates signal transduction from a Toll-like receptor. 
     
     
         9 . The method of  claim 8 , wherein the Toll-like receptor is Toll-like receptor 2. 
     
     
         10 . The method of  claim 8 , wherein the Toll-like receptor is a heterodimer of Toll-like receptor 2 and Toll-like receptor 6. 
     
     
         11 . The method of  claim 8 , wherein the Toll-like receptor is a heterodimer of Toll-like receptor 2 and Toll-like receptor 1. 
     
     
         12 . The method of  claim 8 , wherein the Toll-like receptor is Toll-like receptor 4. 
     
     
         13 . The method of  claim 7 , wherein CVT-E002 induces up-regulation of lymphocytes and antigen-presenting cells, cytokine secretion, secretion of anti-viral factors, or combinations thereof. 
     
     
         14 . A fraction of ginseng for the activation of innate and adaptive immune responses to prevent, treat or ameliorate a condition. 
     
     
         15 . The fraction of  claim 14 , wherein the fraction is made from a ginseng selected from the group consisting of  Panax quinquefolius, Panax trifolia, Panax ginseng, Panax japonicus, Panax schinseng, Panax notoginseng, Panax pseudoginseng, Panax vietnamensis, Panax elegatior, Panax wangianus, Panax bipinratifidus , green or fresh ginseng, white ginseng, and red ginseng. 
     
     
         16 . The fraction of  claim 15 , wherein the fraction is a fraction of  Panax quinquefolius.    
     
     
         17 . The fraction of  claim 16 , wherein the fraction is selected from the group consisting of CVT-E002, PQ 2 , PQ 223  and purified fractions from CVT-E002, PQ 2  and PQ 223 . 
     
     
         18 . The fraction of  claim 17 , wherein the fraction is CVT-E002. 
     
     
         19 . A pharmaceutical composition comprising the fraction of  claim 14  in combination with another medicament or with one or more pharmaceutically acceptable carriers including food items for the activation of innate and adaptive immune responses to prevent, treat or ameliorate a condition. 
     
     
         20 . The composition of  claim 19 , wherein the fraction is made from a ginseng selected from the group consisting of  Panax quinquefolius, Panax trifolia, Panax ginseng, Panax japonicus, Panax schinseng, Panax notoginseng, Panax pseudoginseng, Panax vietnamensis, Panax elegatior, Panax wangianus, Panax bipinratifidus , green or fresh ginseng, white ginseng, and red ginseng. 
     
     
         21 . The composition of  claim 20 , wherein the fraction is a fraction of  Panax quinquefolius.    
     
     
         22 . The composition of  claim 21 , wherein the fraction is selected from the group consisting of CVT-E002, PQ 2 . PQ 223  and purified fractions from CVT-E002, PQ 2  and PQ 223 . 
     
     
         23 . The composition of  claim 22 , wherein the fraction is CVT-E002. 
     
     
         24 . Use of the ginseng fraction of  claim 14  for the preparation of a pharmaceutical composition or a food item for the activation of innate and adaptive immune responses to prevent, treat or ameliorate a condition. 
     
     
         25 . The use of  claim 24 , wherein the condition is selected from the group consisting of an allergy, asthma, viral infection, microbial infection and cancer. 
     
     
         26 . The use of  claim 25 , wherein the viral infection is from a respiratory or mucosally transmitted virus including influenza, corona virus, herpes, respiratory syncytial virus, Rhabdoviridae, and human immunodeficiency virus. 
     
     
         27 . The use of  claim 25 , wherein the fraction is made from a ginseng selected from the group consisting of  Panax quinquefolius, Panax trifolia, Panax ginseng, Panax japonicus, Panax schinseng, Panax notoginseng, Panax pseudoginseng, Panax vietnamensis, Panax elegatior, Panax wangianus, Panax bipinratifidus , green or fresh ginseng, white ginseng, and red ginseng. 
     
     
         28 . The use of  claim 27 , wherein the fraction is a fraction of  Panax quinquefolius.    
     
     
         29 . The use of  claim 28 , wherein the fraction is selected from the group consisting of CVT-E002, PQ 2 , PQ 223  and purified fractions from CVT-E002, PQ 2  and PQ 223 . 
     
     
         30 . The use of  claim 29 , wherein the fraction is CVT-E002. 
     
     
         31 . A method for activating innate and adaptive immune responses to prevent, treat or ameliorate a condition in a subject in need of such activation, comprising administering a ginseng fraction of  claim 14  to the subject. 
     
     
         32 . A method for preventing, treating or ameliorating a condition associated with activation of innate immunity signaling comprising modulating signal transduction from Toll-like receptors by administering a ginseng fraction of  claim 14  to a subject in need of such prevention, treatment or amelioration.

Join the waitlist — get patent alerts

Track US2011086052A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.